Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH)

About AUPH

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducin…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

128

Website

www.auriniapharma.com

Fundamentals

1-day range

$16.26$16.47

Market cap

$1.89B

P/E (trailing)

6.39

P/E (forward)

15.27

EPS (trailing)

$2.29

Dividend yield

—

Beta

1.62

Avg. volume

1.46M

Forecasts

7 analyst ratings

Aurinia Pharmaceuticals Inc Ordinary Shares Competitors

Chosen by industry and closest market cap.

• AUPH

  Aurinia Pharmaceuticals Inc Ordinary Shares

  $16.3

  ▼ 1.09%
  Market cap $1.89BP/E 6.39
  $10.34$19.25
• NBTX

  Nanobiotix S.A. American Depositary Shares

  $41.28

  ▼ 8.59%
  Market cap $1.88BP/E —
  $7.02$47.66
• URGN

  UroGen Pharma Ltd. Ordinary Shares

  $43.61

  ▼ 4.15%
  Market cap $1.88BP/E —
  $15.86$50.81
• STOK

  Stoke Therapeutics Inc. Common Stock

  $31.61

  ▼ 3.01%
  Market cap $1.84BP/E —
  $18.8$40.22
• OCUL

  Ocular Therapeutix Inc. Common Stock

  $10.36

  ▼ 4.25%
  Market cap $1.84BP/E —
  $6.23$16.44
• GENB

  Generate Biomedicines Inc. Common Stock

  $15.33

  ▼ 2.79%
  Market cap $1.84BP/E —
  $11$22.67
• ZBIO

  Zenas BioPharma Inc. Common Stock

  $31.29

  ▼ 4.08%
  Market cap $1.97BP/E —
  $13.5$44.6

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock
  Benzinga · 8/26/2026
• Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
  benzinga · 8/20/2026
• Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
  Benzinga · 8/20/2026
• Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037
  Benzinga · 8/19/2026
• Aurinia Pharmaceuticals Doubles Down On Its Pipeline
  SeekingAlpha · 8/12/2026
• RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16
  Benzinga · 8/7/2026
• Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M Est
  Benzinga · 8/6/2026
• Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate
  Benzinga · 8/6/2026

• Stephen P. Robertson · August 21, 2026 · Sale

  21.0K @ $16.97
• Kathleen Goetz · June 4, 2026 · Grant

  23.9K
• Jeffrey Allen Bailey · June 4, 2026 · Grant

  23.9K
• Craig A. Johnson · June 4, 2026 · Grant

  23.9K
• Nova Tina Susan · June 4, 2026 · Grant

  23.9K
• TANG KEVIN · June 2, 2026 · J

  10.0K @ $1.65
• TANG KEVIN · June 2, 2026 · Buy

  206.0K @ $15.28
• TANG KEVIN · June 1, 2026 · Buy

  99 @ $15.34
• TANG KEVIN · June 1, 2026 · Buy

  343.5K @ $15.28
• TANG KEVIN · May 29, 2026 · Buy

  262.7K @ $15.31
• TANG KEVIN · May 29, 2026 · Buy

  2.3K @ $15.35
• Ryan Cole · May 18, 2026 · Grant

  70.2K
• Ryan Cole · May 18, 2026 · Grant

  116.1K
• Stephen P. Robertson · May 18, 2026 · Grant

  115.5K
• Michael S. Hearne · May 18, 2026 · Grant

  70.2K

Institutional Ownership

March 31, 2026

Total shares held

72.77M

Total value held

$1.05B

Institutional holders

253